希罗达联合奥沙利铂治疗老年转移性结直肠癌  

Xeloda Plus Oxaliplatin as the First-line Treatment of Elderly Patients with Metastatic Colorectal Carcinoma

作　　者：姜虹[1] 周英[1] 杨丽娟[1] 王理伟[1] 高宇[2] 

机构地区：[1]同济大学附属东方医院肿瘤中心,上海200120 [2]上海交通大学医学院,上海200025

出　　处：《医学临床研究》2007年第7期1090-1092,共3页Journal of Clinical Research

摘　　要：[目的]观察希罗达联合奥沙利铂治疗老年（≥70岁）转移性结直肠癌患者的疗效及不良反应。[方法]采用XELOX方案治疗23例老年转移性结直肠癌,d1予奥沙利铂130 mg/m^2,d1-14希罗达1 000 mg/（m^2·d）口服,2次/天,3周1个周期,至少2个周期。[结果]23例患者中,完全缓解1例（4%）,部分缓解9例（39%）,稳定8例（35%）,肿瘤进展5例（22%）。总有效率为43%（10/23）,中位肿瘤进展时间8.1（6.7-11.1）个月,中位总生存期13.9（10.9-17.2）个月。最常见的不良反应为消化道反应、骨髓抑制、神经感觉障碍及手足综合征,多为Ⅰ-Ⅱ度。[结论]XELOX是治疗老年转移性结直肠癌安全有效的化疗方案。[Objective]To evaluate the efficacy and tolerability of the combination of xeloda and oxaliplatin as the first-line treatment of elderly patients with metastatic colorectal carcinoma.[Methods]A total of 23 elderly（≥70 years） patients received oxaliplatin 130 mg/m2 on day 1 followed by oral xeloda 1000mg/m2 twice daily on day 1~14,every 3 weeks as a cycle for at least 2 cycles.[Results]Of the twenty-three patients enrolled,the overall response rate was 43% with complete and partial response rate of 4% and 39%,respectively.The median time to tumor progress was 8.1 months,and the median overall survival time was 13.9 months.The common adverse reactions were grade 1 or 2 peripheral neuropathy,neutropenia,anaemia,diarrhoea,nausea,and Hand-foot syndrome.[Conclusion]The combination of xeloda and oxaliplatin shows significant antitumor activity and a favorable toxicity profile in patients with metastatic carcinoma of the colorectum.

关 键 词：结肠直肠肿瘤/药物疗法 有机铂化合物/投药和剂量 

分 类 号：R735.35[医药卫生—肿瘤]